Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu & Li Bai

Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to explore factors associated with efficacy. Between January 2015 and February 2017, totally 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction (GEJ) were enrolled and followed up retrospectively after failing at least two lines of systemic therapy. The mPFS was 2.65 months (95%CI 1.66–3.54), and mOS was 5.8 months (95%CI 4.77–6.83). Two patients achieved partial response, and nineteen achieved stable disease. The disease control rate (DCR) was 58.3%, and objective response rate (ORR) was 5.6%. Common grade adverse events were hypertension (38.9%), proteinuria (36.1%), and neutropenia (33.3%). And the most common adverse events over grade 3 were hand-foot syndrome (8.3%), anemia (5.6%), and diarrhea (5.6%). No treatment-related death was documented during the drug administration. Exploratory analyses indicated patients treated with antiangiogenic therapy previously were more likely to benefit from apatinib.

Gastric cancer (GC), including cancer in gastroesophageal junction (GEJ), is a common digestive system neoplasm, which is the third leading cause of cancer related death worldwide. Surgery is considered to be the only radical treatment for early diseases, however, recurrence incidence remains high in patients after the multidisciplinary approach involving radical resection and perioperative or adjuvant treatment, not mention to that approximately 80% of patients with locally advanced or metastatic GC can barely receive benefit from gastrostomy. Chemotherapy typically based on platinum or taxanes, has prolonged the average overall survival time to nearly 12 months, showing a limited effect. At present, new approaches are focusing on molecularly driven therapies.

Angiogenesis is one of the most important mechanisms for the emergence and development of malignant tumors. Angiogenesis contributes to the processes of tumor proliferation, metastasis, and migration, acting as nutrient supply for cancer cells. Therefore, antiangiogenic therapy has become a prior choice to conflict with cancers, and a few angiogenesis inhibitors have shown efficacy in lung, breast, and colon cancers. Although in gastric cancer the evidence is still inconclusive, antiangiogenic treatment is also considered a promising therapy.

Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). Previous phase II and III clinical trials has shown that its efficacy and safety in patients with chemotherapy-refractory advanced or metastatic gastric carcinoma when compared with placebo. And in these trials, the therapeutic effect of apatinib on overall survival was mainly derived from prolonged progression-free survival. However, the treatment of apatinib in the real world is still unclear.

Therefore, we carried out this observational study to give more clinical evidence of the treatment of apatinib in patients with gastric cancer and cancer of GEJ in the real world.

Results

Patients and tumor characteristics. A total of 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) who had progressed or relapsed after undergoing at least two lines of systemic therapy in Oncology Department of the Chinese PLA General Hospital (PLAGH) between January 2015 and February 2017 were included. The median age of the patients was 58 years old, ranging from 38 to 75, and 69.4% were male. All patients were histologically confirmed adenocarcinoma, with or without some other components, which included mucinous adenocarcinoma or signet ring cell carcinoma. There were 8
patients with Her2 positive status (22.2%), 12 patients with Her2 negative status (33.3%), except that 16 patients didn't carry out this test due to personal preference, insufficient biopsy specimen or financial difficulties (44.4%).

All patients had advanced or metastatic disease and the most common metastatic sites were liver (55.6%), distant lymph nodes (50.0%) and peritoneum (22.2%). Thirty-one patients had an ECOG performance status of 0/1 (86.1%), and 5 patients' ECOG PS was 2/3 (13.9%).

All patients had received previous treatment, including but not limited to gastrostomy, chemotherapy, radiotherapy and targeted therapy. Twenty-four patients (66.7%) hadn't undergone any surgery while 10 patients (27.8%) had radical surgery and 2 patients (5.6%) had palliative surgery. Five patients (13.9%) had radiotherapy due to positive surgical margin. Most patients had received doublet or triplet chemotherapeutics in the first and second line therapy and the most important chemotherapeutics were Platinum, Taxanes and Fluorouracil. All 8 patients with positive Her2 status had received anti-Her2 therapy in the first or second line according to guidelines. Nine patients (25%) had undergone antiangiogenic therapy in first or second line therapy involving bevacizumab and apatinib. In these 9 patients' previous treatment, bevacizumab was combined with therapy including XELOX, DOF and Everolimus, while apatinib was applied alone.

Complete clinical and pathologic characteristics at the initiation of apatinib therapy are shown in Table 1, and the previous treatment details are provided in Tables 2 and 3.
Treatment administration. Twenty-one patients (58.3%) had started the apatinib therapy from the dosage of 500 mg, and 13 (36.1%) from 250 mg, and 2 (5.6%) from a dosage that was higher than 500 mg. Five patients (13.9%) had decreased their initial dosage for the reason of intolerable toxicity. Twelve patients (38.9%) had received concomitant chemotherapy on physicians’ choices, including 2 patients using doublet chemotherapy. Combined chemotherapy involved Fluorouracil (8 patients, 22.2%), Platinum (3 patients), Irinotecan (2 patients, 5.6%) and temozolomide (1 patient). Two patients combined with other treatment involving radiotherapy (1 patient) and ablation (1 patient). At the cutoff time (April 20th, 2017), all these 36 patients had discontinued apatinib therapy on account of disease progression.

Efficacy. At the time of analysis, all patients had progressed from apatinib therapy and 28 patients (77.8%) had died mainly because of tumor progression. The median PFS was 2.65 months (95%CI 1.66–3.54), and the median OS was 5.8 months (95%CI 4.77–6.83). The Kaplan-Meier curves of PFS and OS are shown in Figs 1 and 2. All the 36 patients had been evaluated by imageological examination. Two patients (5.56%) achieved PR, 19 patients (52.78%) had SD, and 15 patients (41.67) were reported as PD after the apatinib therapy. These resulted in an ORR of 5.56% and a DCR of 58.33%.

As shown in Table 4, seven factors including age group, prior gastrostomy, liver metastasis, peritoneal metastasis, previous targeted therapy (anti-Her2 and antiangiogenic) and combination therapy, were brought into our exploratory analysis in consideration of clinical practice and previous study. Cox regression model showed a significant association between apatinib therapy PFS and prior antiangiogenic therapy (adjusted HR = 2.935, 95%CI 1.047–8.229, P = 0.041). Besides that, factors considered as potential markers associated with the efficiency like liver metastasis, peritoneal metastasis and number of metastasis didn’t make any differences in our study, probably because of small sample size. Data of univariate analysis and multivariate analysis were shown in Table 4.

Safety. All 36 patients were included in safety analysis. Toxicities were generally well tolerated. Dose modifications resulting from toxicity occurred in 5 patients. The reasons for dosage decrement were hypertension, proteinuria, leukopenia, and thrombocytopenia.

Table 2. Previous treatment (N = 36). (Antiangiogenic therapy included bevacizumab or apatinib therapy).

| Treatment                  | No. | %     |
|----------------------------|-----|--------|
| Prior gastrostomy          |     |        |
| Radical surgery            | 10  | 27.8%  |
| Palliative surgery         | 2   | 5.6%   |
| No surgery                 | 24  | 66.7%  |
| Prior radiotherapy         |     |        |
| Yes                        | 5   | 13.9%  |
| No                         | 31  | 86.1%  |
| Prior chemotherapy         |     |        |
| 2 lines                    | 25  | 69.4%  |
| 3 lines                    | 8   | 22.2%  |
| 4 lines                    | 2   | 5.6%   |
| 5 lines                    | 1   | 2.8%   |
| Prior targeted therapy     |     |        |
| Antiangiogenic therapy     | 9   | 25.0%  |
| Anti-Her2 therapy          | 8   | 22.2%  |
| No targeted therapy        | 19  | 52.8%  |

Table 3. Previous antiangiogenic treatment details (N = 9). (A: apatinib; B: bevacizumab; XELOX: oxaliplatin and capectibine; DOF: docetaxel, oxaliplatin, and fluorouracil; D: docetaxel; S: S-1; Iri: Irinotecan; X: capectabine; O: oxaliplatin).

| Patient | Study line | Antiangiogenic therapy before study | Apatinib therapy in study line | PFS  |
|---------|------------|-------------------------------------|--------------------------------|------|
| 1       | 3          | B + XELOX                           | A                              | 1.2  |
| 2       | 3          | B + DOF                             | A                              | 3.6  |
| 3       | 3          | B + D                               | A + S                          | 3    |
| 4       | 4          | B + everolimus                       | A + Iri                        | 2.2  |
| 5       | 3          | A                                   | A + S                          | 3.6  |
| 6       | 3          | A                                   | A + Iri                        | 3.4  |
| 7       | 3          | A                                   | A + X                          | 8.6  |
| 8       | 3          | A                                   | A + D                          | 5.7  |
| 9       | 4          | A                                   | A + O                          | 1.8  |

Table 4. Previous treatment (N = 36). (Antiangiogenic therapy included bevacizumab or apatinib therapy).
The most common adverse events included hypertension (38.9%), proteinuria (36.1%), nausea and vomiting (36.1%), and leukopenia (33.3%). Grade 3 to 4 AEs with the incidences of 5% or greater were hand-foot syndrome (8.3%), anemia (5.6%) and diarrhea (5.6%). Only one patient occurred grade 4 AE, hand-foot syndrome.

These findings are consistent with those from previous clinical trials. No treatment-related death was documented during the drug administration. All adverse events are listed in Table 5.
Fluoropyrimidine-based, platinum-based and taxanes-based chemotherapy, whether two-drug regimens or three-drug regimens, have been widely used in routine first line treatment for locally advanced or metastatic gastric cancer. NCCN guidelines also recommend six preferred regimens for second line therapy. However, only a few studies assessed third-line choices for gastric cancer. Sakura Iizumi reported taxane monotherapy including paclitaxel and nab-paclitaxel for GC in 3rd line, showing efficacy (mPFS = 2.0 mo, mOS = 4.5 mo) and safety (G3/4 AE ratio = 33.3%) in a multicenter retrospective study. Takashi Nishimura reported Irinotecan monotherapy efficacy (mPFS = 2.3 mo, mOS = 4.0 mo, ORR = 3%, DCR = 22%) and safety (G3/4 AEs: neutropenia 27%, febrile neutropenia 12%, anorexia 12%). Eun Joo Kang reported FOLFIRI efficacy (mPFS = 2.1 mo, mOS = 5.6 mo, ORR = 9.6%) and safety (G3/4 AE: myelosuppression 36.7%). All these chemotherapies have attempted to achieve low toxicity and good efficacy, which could be optimized and improved for further.

Our study is a real-world observation of the efficacy and safety of the apatinib therapy for patients with advanced gastric cancer or advanced GEJ cancer. In this study of the third or more line treatment for gastric cancer, apatinib therapy led to a median PFS of 2.65 months (95%CI 1.66–3.54), a median OS of 5.8 months (95%CI 4.77–6.83), an ORR of 5.56% and a DCR of 58.33%. Common adverse events were hypertension (38.9%), proteinuria (36.1%), and neutropenia (33.3%). And the most common adverse events over grade 3 were hand-foot syndrome (8.3%), anemia (5.6%), and diarrhea (5.6%). As shown in Table 6, our apatinib therapy seems to be nearly efficient and safe compared with phase II and III trials. However, this is a real world study, an observational study, which mingled with some complicated factors. There is still some dissimilitude between them. On one hand, patients’ performance status before apatinib in this study was much worse than in clinic trails. Five

| Parameters       | PLAGH 850 mg QD | Phase II Trial 850 mg QD | Phase III Trial 425 mg BID | Phase III Trial 850 mg QD |
|------------------|-----------------|----------------------------|----------------------------|---------------------------|
| No. of patients  | 36              | 47                         | 46                         | 176                       |
| Survival         |                 |                            |                            |                           |
| median OS (months) | 5.8            | 4.83                       | 4.27                       | 6.5                       |
| 95% CI           | 4.77–6.83       | 4.03–5.97                  | 3.83–4.77                  | 4.8–7.6                   |
| median PFS (months) | 2.65         | 3.67                       | 3.2                        | 2.6                       |
| 95% CI           | 1.66–3.54       | 2.17–6.80                  | 2.37–4.53                  | 2.0–2.9                   |
| Responses        |                 |                            |                            |                           |
| ORR              | 5.56%           | 6.38%                      | 13.04%                     | 2.84%                     |
| DCR              | 58.33%          | 51.06%                     | 34.78%                     | 42.03%                    |
| Adverse events   |                 |                            |                            |                           |
| Hypertension     | Grade ≥ 1 38.90% | 40.43%                     | 39.13%                     | 35.20%                    |
|                  | Grade ≥ 3 2.80%  | 8.51%                      | 10.87%                     | 4.50%                     |
| Proteinuria      | Grade ≥ 1 36.10% | 27.66%                     | 34.78%                     | 47.70%                    |
|                  | Grade ≥ 3 2.80%  | 2.13%                      | 4.35%                      | 2.30%                     |
| Hand-foot syndrome | Grade ≥ 1 19.40% | 25.53%                     | 45.65%                     | 27.80%                    |
|                  | Grade ≥ 3 8.30%  | 4.26%                      | 13.04%                     | 8.50%                     |

Table 5. Adverse events (N = 36).

Table 6. Comparison with previous studies. (Survival and response data in Phase II Trial were from intent-to-treat (ITT) patients. In Phase III Trial, survival data were from the full analysis set (FAS) patients, and response data were assessed by investigators).

Discussion
Fluoropyrimidine-based, platinum-based and taxanes-based chemotherapy, whether two-drug regimens or three-drug regimens, have been widely used in routine first line treatment for locally advanced or metastatic gastric cancer. NCCN guidelines also recommend six preferred regimens for second line therapy. However, only a few studies assessed third-line choices for gastric cancer. Sakura Iizumi reported taxane monotherapy including paclitaxel and nab-paclitaxel for GC in 3rd line, showing efficacy (mPFS = 2.0 mo, mOS = 4.5 mo) and safety (G3/4 AE ratio = 33.3%) in a multicenter retrospective study. Takashi Nishimura reported Irinotecan monotherapy efficacy (mPFS = 2.3 mo, mOS = 4.0 mo, ORR = 3%, DCR = 22%) and safety (G3/4 AEs: neutropenia 27%, febrile neutropenia 12%, anorexia 12%). Eun Joo Kang reported FOLFIRI efficacy (mPFS = 2.1 mo, mOS = 5.6 mo, ORR = 9.6%) and safety (G3/4 AE: myelosuppression 36.7%). All these chemotherapies have attempted to achieve low toxicity and good efficacy, which could be optimized and improved for further.

Our study is a real-world observation of the efficacy and safety of the apatinib therapy for patients with advanced gastric cancer or advanced GEJ cancer. In this study of the third or more line treatment for gastric cancer, apatinib therapy led to a median PFS of 2.65 months (95%CI 1.66–3.54), a median OS of 5.8 months (95%CI 4.77–6.83), an ORR of 5.56% and a DCR of 58.33%. Common adverse events were hypertension (38.9%), proteinuria (36.1%), and neutropenia (33.3%). And the most common adverse events over grade 3 were hand-foot syndrome (8.3%), anemia (5.6%), and diarrhea (5.6%). As shown in Table 6, our apatinib therapy seems to be nearly efficient and safe compared with phase II and III trials. However, this is a real world study, an observational study, which mingled with some complicated factors. There is still some dissimilitude between them. On one hand, patients’ performance status before apatinib in this study was much worse than in clinic trails. Five
patients ECOG PS was 2/3 (13.9%) in our study, while all patients in previous clinic trails scored 0 or 1. In our study, 83.3% of the patients had more than two metastatic lesions, while the corresponding rate in phase III trial was 21%. Only 33.3% the patients in present study had received surgery, involving radical and palliative surgery at the same time, while the rate in phase III trial was 69.3%. Besides that, patients in our study were heavily pre-treated in consideration of the three patients who had received over four lines chemotherapy. These discrepancies illustrate patients in real world perform worse and have more visceral metastases and higher tumor burden, and highlight the gap in the baseline of apatinib treatments between the randomized controlled trials and real-world treatment. On the other hand, dose titration was more flexibly in our study although initial apatinib dosage of 500 mg once daily in our study was situated between the two clinic trials, which could be increased to 750 mg or decreased to 250 mg. Combination with other therapy was also allowed according to their actual performance status in our study, which wasn't covered in trials. We believed it was these rectifications in the treatment method that we had obtained similar efficacy results with previous trials, even if patients were heavily pretreated and performed worse. Moreover, these rectifications, especially dose up-regulation and combination chemotherapy, didn't increase the incidence of adverse events, which meant a well-behaved tolerance of patients.

Preclinical data demonstrated that vascular endothelial growth factor (VEGF) was continuously expressed during oncogenesis, tumor growth and metastasis, by facilitating tumor angiogenesis, and prolonged exposure to VEGF inhibitors could delay tumor growth and even maintain tumor regression31–33. Continuous angiogenic blockade strategy has been evaluated in the clinical settings and been proved to benefit patients with metastatic colorectal cancer34–36, but there is still no evidences directly supporting this concept in gastric cancer. In our exploratory analysis, multivariate analysis indicated prior antiangiogenic therapy was an independent factor associated with PFS of apatinib therapy. Nine patients had undergone antiangiogenic therapy in prior treatment, involving apatinib combined with chemotherapy or targeted therapy regularly, and 5 received apatinib alone in second or third line before they were brought into our study. After disease progression from previous treatment, they continued antiangiogenic therapy with apatinib and benefited from it, whether a small-molecule TKIselectively targeting VEGF-R (apatinib) or a monoclonal antibody targeting VEGF ligand (bevacizumab) was used before. Bevacizumab as a continuous therapy had been discussed in the ML18147 trial and the BEBYP trial, in which bevacizumab was continued or reintroduced after the first progression of bevacizumab interruption, and bevacizumab plus chemotherapy significantly prolonged patients' OS and PFS (OS in ML18147, B + C 11.2 mo vs. C 9.8 mo, HR = 0.81, 95%CI 0.69–0.94, P = 0.0062; PFS in BEBYP, B + C 6.8 mo vs. C 5.0 mo, HR = 0.70, 95%CI 0.52–0.95, P = 0.010)24,27. But this strategy still needs more exploration and discussion.

Antiangiogenic therapies, no matter monoclonal antibodies or tyrosine kinase inhibitors, were usually combined with chemotherapy, because of the poor efficiency used alone. Preclinical models demonstrated that sustained monoclonal antibody antiangiogenic treatment could create or remodel an environment suitable for normalization of the stable vascular endothelial cells, leading to increased tumor uptake of chemotherapy, which could be a possible explanation for the beneficial effect of this combination therapy24,26. However, the combined therapy strategy involving antiangiogenic and chemo therapy in gastric cancer has long been controversies. Most evidences were inclined to support the counterview. Monoclonal antibodies such as bevacizumab or ramucirumab, neither used alone nor combined with chemotherapy could significantly improve patients' survival. For instance, in AVATAR study, ST03 study, REGARD study and RAINBOW study, addition of bevacizumab or ramucirumab didn't show any advantages30,32 and the same results also occurred in TKIs, like orantinib, pazopanib and sorafenib33–36. Only two researches showed that monotherapy of antiangiogenic TKIs could significantly prolong the PFS as the primary endpoint, including apatinib (Phase III, in 3rd line, apatinib 2.6 mo vs. placebo 1.8 mo, HR = 0.44, 95%CI 0.54–0.94, P < 0.001) and regorafenib (Phase II, in 2nd or 3rd line, regorafenib 2.6 mo vs. placebo 0.9 mo, HR = 0.40, 95%CI 0.28–0.59, P < 0.001)11,37. In our study, fourteen patients added other systemic and local treatment, including chemotherapy, radiotherapy and ablation to apatinib therapy. However the combination didn't significantly prolong patients' PFS compared to apatinib, which was ascribed to differences in tumor biology and subsequent treatment between the first and second line settings, or limitations of study designs and patient selection. We also noticed the five patients in Table 3 who progressed from apatinib monotherapy but benefited from the combination of apatinib plus chemotherapy, and we attributed this to the enhancement of apatinib to conventional chemotherapy. In preclinical data, apatinib significantly increased the intracellular accumulation of rhodamine 123 and doxorubicin in cells by down-regulating the expression of P-glycoprotein (P-gp, ABCB1) or breast cancer resistance protein (BCRP, ABCG2), then reversed the multidrug resistance (MDR) and significantly enhanced the cytotoxicity substrate drugs38,39. Further studies remain needed.

Consequently, rigorous randomized controlled trials are needed to establish whether apatinib with an alternative chemotherapy regimen can benefit patients more than apatinib monotherapy, whether apatinib with or without an alternative chemotherapy regimen can benefit patients who have progressed after previous antiangiogenic therapy, or whether antiangiogenic therapy history can predict the advantaged population of apatinib therapy.

In spite of the inspiring improvement of PFS and DCR, apatinib has also exposed patients to its toxicity. It draws more and more attention of physicians and patients before considering the administration of apatinib. Hypertension, proteinuria and hand-foot syndrome are the most common AEs in antiangiogenic therapy7,8. In our present study, the safety profile was almost consistent with previous clinical trials, except that the incidence of certain AE hand-foot syndrome was a little lower11,12. Dealing with hand-foot syndrome has always been a tough thing. We attribute the lower incidence of hand-foot syndrome to prophylactic treatment, including moisturization for hand and foot, herbal medicine immersion and supplementation of multi-vitamin. Hypertension, proteinuria were treated in accordance with standard principles. In addition, hematologic toxicities related to apatinib in our study included leucopenia and neutropenia, while common non-hematologic toxicities involved elevated transaminase, hyperbilirubinemia, nausea and vomiting and diarrhea. Given that 66.7% of our patients not received any surgery, the incidence of bleeding events had not increased obviously compared to clinical trials.
It indicates that apatinib does not increase risks associated to antiangiogenic therapy and can be tolerated by patients with heavy tumor burden of primary lesion. Besides that, a puzzle emerged in the present study, how to define the bleeding. For instance, should we categorize positive result of fecal occult blood as hemorrhage in digestive tract? On one side, primary lesion itself of advanced gastric cancer could lead a positive result, which might lead to an overestimated incidence. On the other side, in clinic work, fecal occult blood is usually not monitored as frequently as other laboratory examination such as blood routine examination. Only when patients noticed the red change of their fecal color, or when they experienced abdominal pain or diarrhea symptom, this test would be monitored regularly. Therefore, the incidence was highly likely to be underestimated. On the whole, from the observations in our study and previous trials, we can see that the AEs of apatinib are manageable, based on physician awareness and patient education.

This study offers first-hand efficacy and safety data of apatinib in the real world, which are informative for physicians and patients. Secondly, exploratory analysis provides several clues for selection of patients who are more likely to benefit from apatinib. Thirdly, safety analysis of this study helps gain better knowledge and familiarization with possible side effects and how to deal with them. However, this study was subject to limitations of its retrospective observational methodology, including potential missing data, possible information bias, small sample size and lack of control group. Moreover, quality of life was not formerly assessed, which could have provided more comprehensive information on apatinib toxicities. Furthermore, potential crowds remained to be crystallized.

Taken together, the efficacy and safety profiles of apatinib in this study were similar to previous clinic trials. Heavily pretreated advanced gastric cancer patients can tolerate and benefit from apatinib therapy, which makes apatinib therapy a promising option. And the specific application strategies need further exploration.

**Methods**

**Patients.** This is a retrospective real world study approved by the ethics committee of Chinese PLA General Hospital (PLAGH). Patients with advanced gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction who had progressed or relapsed after undergoing at least two lines of systemic therapy in accordance with the recommendations and guidelines of NCCN (National Comprehensive Cancer Network) in Oncology Department of the Chinese PLAGH between January 2015 and February 2017 were included. Data were obtained from patients' medical history. Demographic and clinical characteristics and previous treatment were evaluated in all patients.

**Treatment.** Apatinib therapy was initiated from an oral administration dosage of 500 mg once a day, 4 weeks for a cycle, which could be adjusted according to patients' actual performance status ranging from 750 mg to 250 mg once daily. The daily dosage could be decreased to 250 mg due to patients’ severe adverse events. The chemotherapy or targeted therapy combined with apatinib was hinged on physicians' determination based on patients' situations. Informed consent was reviewed and signed by the patients or their legal guardian before apatinib therapy.

Only patients who had finished at least one cycle apatinib therapy and evaluated the efficacy were included in this study.

**Efficacy and safety.** The efficacy of apatinib was evaluated including progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR). PFS was defined as time from initiation of apatinib to disease progression or death, whichever occurred first. OS was defined as the duration from the time of treatment initiation to the time of death of any cause or the last follow-up time. Tumor responses were evaluated by computed tomography (CT), magnetic resonance imaging (MRI), bone scan and physical examination every cycle until disease progression, categorized as complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) which were confirmed by physicians according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. ORR was estimated as the percentage of CRs and PRs. DCR was considered as the percentage of CRs, PRs, and SDs.

All adverse events (AEs) were reviewed and determined from patients' medical history and laboratory examination results or from telephone follow-up according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

**Statistical analysis.** PFS and OS and their corresponding 95% confidence intervals (CIs) were estimated by Kaplan-Meier method. The hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were estimated using the Cox's proportional hazards regression model.

Quantitative variables are presented as median (range) or number of patients (percentage).

Exploratory analysis for potential factors to predict PFS of Apatinib was a two-step process, consisting of univariate analysis and multivariate analysis. Univariate analyses were performed with the Log-rank test. Factors included in the univariate analysis were age (<median = 58 vs. ≥58), prior gastropstyomy (yes vs. no), liver metas-tasis (yes vs. no), peritoneal metastasis (yes vs. no), previous anti-Her2 therapy (yes vs. no), previous antiangiogenic therapy (yes vs. no) and combination therapy (apatinib only vs. combined with chemo or other targeted therapy). Multivariate analyses were performed with the Cox's proportional hazards regression model based on results of the univariate analyses. All crude and adjusted HRs and 95% CIs were estimated. All statistical analyses were two sided. HR < 1 implied a lower risk of progression for patients. A statistical significance cutoff of p = 0.05 was used to retain the variables in the final model.

Responses and AEs were both aggregated in the form of frequency counts and percentages. The ORR and DCR analyses were based on frequency counts.

All the statistical analyses were performed using SPSS for Windows (version 21; IBM®, Armonk, NY).
References

1. Ferlay, J., Soerjomataram, I. & Dikshit, R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. **136**(5), E359–86 (2015).

2. van Hagen, P., Hulshof, M. C. & van Lanschot, J. J. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med*. **366**(22), 2074–84 (2012).

3. Wagner, A. D. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol*. **24**(18), 2903–9 (2006).

4. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell*. **100**(1), 57–70 (2000).

5. Wong, H. & Yau, T. Molecular targeted therapies in advanced gastric cancer: does tumor histology matter. *Therap Adv Gastroenterol*. **6**(1), 15–31 (2013).

6. De Vita, F. Di, M. N. & Fabbrozzi, A. et al. Clinical management of advanced gastric cancer: the role of new molecular drugs. *World J Gastroenterol*. **20**(40), 14537–58 (2014).

7. Ohtsu, A., Shah, M. A. & Van Cutsem, E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol*. **29**(30), 3968–76 (2011).

8. Fuchs, C. S., Tomasek, J. & Yong, C. J. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. **383**(9911), 31–9 (2014).

9. Martin-Richard, M., Gallego, R. & Pericay, C. et al. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. *Invest New Drugs*. **31**(6), 1573–9 (2013).

10. Alisina, M., Hierro, C. & Tabernero, J. Antiangiogenic therapies in gastric cancer: trusting the pathway. *Ann Oncol*. **27**(12), 2141–2143 (2016).

11. Li, J., Qin, S. & Xu, J. et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. *J Clin Oncol*. **34**(13), 1448–54 (2016).

12. Li, J., Qin, S. & Xu, J. et al. Apatinib for chemotheray-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. *J Clin Oncol*. **34**(26), 2319–25 (2016).

13. Huang, L. et al. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. *Oncotarget*. **8**, 29346–29354 (2017).

14. Enzinger, P. C. et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. *J Clin Oncol*. **34**, 2736–2742 (2016).

15. Kim, G. M. et al. A randomized phase II trial of S-1 oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer*. **48**, 518–526 (2012).

16. Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol*. **26**, 1435–1442 (2008).

17. Kang, Y. K. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol*. **20**, 666–673 (2009).

18. Iizumi, S., Takashima, A. & Narita, Y. et al. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemother Pharmacol. (2017).

19. Nishimura, T., Iwasa, S. & Nagashima, K. et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. *Gastric Cancer*. **20**(4), 655–662 (2017).

20. Kang, E. J., Im, S. A. & Oh, D. Y. et al. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidines, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. *Gastric Cancer*. **16**(4), 581–9 (2013).

21. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer*. **3**, 401–410 (2003).

22. Bagri, A. et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. *Clin Cancer Res*. **16**, 3887–3900 (2010).

23. Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J Clin Invest*. **105**, R15–24 (2000).

24. Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol*. **14**, 29–37 (2013).

25. Kubicks, S., Greil, R. & André, T. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. *Ann Oncol*. **24**(9), 2342–9 (2013).

26. Grotthey, A., Sugrue, M. M. & Purdie, D. M. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). *J Clin Oncol*. **26**(33), 5326–34 (2008).

27. Masi, G. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BABY trial. *Ann Oncol*. **26**, 724–730 (2015).

28. Carmellet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov*. **10**, 417–427 (2011).

29. Tong, R. T. et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. *Cancer Res*. **64**, 3731–3736 (2004).

30. Wilke, H., Duro, K. & Van Cutsem, E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. **15**(11), 1224–35 (2014).

31. Cunningham, D., Stennin, S. P. & Smyth, E. C. et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. *Lancet Oncol*. **18**(3), 357–370 (2017).

32. Shen, L., Li, J. & Xu, J. et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). *Gastric Cancer*. **18**(1), 168–76 (2015).

33. Shen, L. T., Oh, D. Y. & Ryu, M. H. et al. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. *Cancer Res Treat*. (2017).

34. Koizumi, W., Yamaguchi, K. & Hosaka, H. et al. Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. *Br J Cancer*. **109**(8), 2079–86 (2013).

35. Yi, J. H., Lee, J. & Lee, J. et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. *Br J Cancer*. **106**(9), 1469–74 (2012).

36. Yoon, H. H., Bendell, J. C. & Braiteh, F. S. et al. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. *Ann Oncol*. **27**(12), 2196–2203 (2016).
37. Pavlakis, N. et al. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. *J Clin Oncol* **34**, 2728–2735 (2016).

38. Mi, Y. J. et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. *Cancer Res* **70**, 7981–7991 (2010).

39. Tong, X. Z. et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. *Biochem Pharmacol* **83**, 586–597 (2012).

40. Lei, X., Wang, F. & Ke, Y. et al. The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*. **96**(10), e6301 (2017).

**Acknowledgements**

This research was supported by the projects from National Key Research and Development (R&D) Plan (2016YFC1303602).

**Author Contributions**

Conception and design: Yong Zhang, Yi Hu and Li Bai; Collection and assembly of data: Yong Zhang, Chun Han, Juan Li and Li Zhang; Data analysis and interpretation: Yong Zhang, Sisi Ye and Li Bai; Manuscript preparation: Yong Zhang and Lijie Wang; Revision of the manuscript: Yong Zhang, Chun Han and Li Bai; Final approval of manuscript: All authors.

**Additional Information**

**Competing Interests:** The authors declare that they have no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017